Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medical Oncology | 25 | 2023 | 2320 | 2.490 |
Why?
|
Neoplasms | 38 | 2024 | 22140 | 1.990 |
Why?
|
Quality Improvement | 18 | 2022 | 3808 | 1.280 |
Why?
|
Antineoplastic Agents | 16 | 2019 | 13632 | 1.190 |
Why?
|
Teaching Rounds | 2 | 2022 | 276 | 1.190 |
Why?
|
Cancer Care Facilities | 6 | 2018 | 422 | 1.180 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 3 | 2016 | 92 | 1.140 |
Why?
|
Critical Pathways | 2 | 2022 | 475 | 1.130 |
Why?
|
Medical Errors | 2 | 2023 | 1263 | 0.940 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 1 | 2024 | 17 | 0.930 |
Why?
|
Delivery of Health Care | 8 | 2020 | 5333 | 0.880 |
Why?
|
Quality of Health Care | 8 | 2021 | 4320 | 0.740 |
Why?
|
Malpractice | 2 | 2023 | 553 | 0.740 |
Why?
|
Patient Rights | 1 | 2020 | 126 | 0.650 |
Why?
|
Comprehensive Health Care | 1 | 2018 | 123 | 0.590 |
Why?
|
Lung Neoplasms | 6 | 2022 | 13385 | 0.590 |
Why?
|
Physician-Patient Relations | 3 | 2021 | 3253 | 0.570 |
Why?
|
Palliative Care | 4 | 2021 | 3599 | 0.520 |
Why?
|
Terminal Care | 4 | 2016 | 1760 | 0.490 |
Why?
|
Quality Assurance, Health Care | 7 | 2015 | 2164 | 0.480 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 561 | 0.480 |
Why?
|
Staff Development | 1 | 2016 | 227 | 0.460 |
Why?
|
Leadership | 4 | 2021 | 1385 | 0.450 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5321 | 0.430 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 1069 | 0.430 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2021 | 940 | 0.420 |
Why?
|
Risk Management | 3 | 2023 | 557 | 0.410 |
Why?
|
Hospitalization | 6 | 2018 | 10707 | 0.400 |
Why?
|
Attitude of Health Personnel | 4 | 2021 | 3885 | 0.380 |
Why?
|
Decision Support Systems, Clinical | 2 | 2017 | 1172 | 0.330 |
Why?
|
Certification | 1 | 2013 | 418 | 0.330 |
Why?
|
Decision Support Techniques | 2 | 2019 | 2004 | 0.320 |
Why?
|
Humans | 71 | 2024 | 761208 | 0.320 |
Why?
|
Motivation | 1 | 2019 | 2002 | 0.320 |
Why?
|
Societies, Nursing | 3 | 2013 | 22 | 0.320 |
Why?
|
Education, Medical, Continuing | 1 | 2014 | 825 | 0.310 |
Why?
|
Practice Guidelines as Topic | 5 | 2014 | 7400 | 0.300 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2756 | 0.300 |
Why?
|
Faculty, Medical | 1 | 2016 | 1205 | 0.290 |
Why?
|
Information Dissemination | 1 | 2016 | 1129 | 0.290 |
Why?
|
Activities of Daily Living | 1 | 2016 | 2420 | 0.290 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2024 | 4014 | 0.270 |
Why?
|
Ambulatory Care | 2 | 2014 | 2770 | 0.270 |
Why?
|
Drug Therapy | 1 | 2009 | 503 | 0.270 |
Why?
|
Telemedicine | 2 | 2021 | 3051 | 0.260 |
Why?
|
Program Evaluation | 5 | 2018 | 2489 | 0.260 |
Why?
|
Health Care Costs | 3 | 2017 | 3239 | 0.240 |
Why?
|
Decision Making | 1 | 2019 | 3931 | 0.240 |
Why?
|
Caregivers | 1 | 2016 | 2244 | 0.230 |
Why?
|
Administration, Oral | 5 | 2018 | 4015 | 0.230 |
Why?
|
Education, Medical | 1 | 2015 | 1725 | 0.220 |
Why?
|
Bone Marrow Examination | 2 | 2014 | 155 | 0.220 |
Why?
|
Medicare | 3 | 2016 | 6773 | 0.220 |
Why?
|
Insurance, Liability | 1 | 2023 | 100 | 0.210 |
Why?
|
Hospital Mortality | 2 | 2016 | 5295 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.200 |
Why?
|
Health Personnel | 1 | 2016 | 3337 | 0.200 |
Why?
|
Acetonitriles | 1 | 2021 | 54 | 0.190 |
Why?
|
United States | 15 | 2016 | 72339 | 0.190 |
Why?
|
Stress, Psychological | 1 | 2016 | 4487 | 0.190 |
Why?
|
Quality of Life | 2 | 2021 | 13367 | 0.180 |
Why?
|
Efficiency, Organizational | 2 | 2016 | 695 | 0.180 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2024 | 646 | 0.170 |
Why?
|
Communication | 3 | 2023 | 3872 | 0.170 |
Why?
|
Massachusetts | 4 | 2016 | 8837 | 0.160 |
Why?
|
Medically Underserved Area | 1 | 2021 | 254 | 0.160 |
Why?
|
Narration | 1 | 2021 | 218 | 0.160 |
Why?
|
Fluorouracil | 1 | 2024 | 1642 | 0.160 |
Why?
|
Specimen Handling | 2 | 2014 | 702 | 0.160 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5425 | 0.150 |
Why?
|
Female | 22 | 2024 | 392544 | 0.150 |
Why?
|
Feedback | 1 | 2022 | 790 | 0.150 |
Why?
|
Documentation | 2 | 2022 | 900 | 0.150 |
Why?
|
Societies, Medical | 4 | 2016 | 3923 | 0.150 |
Why?
|
Morbidity | 1 | 2022 | 1751 | 0.140 |
Why?
|
Arizona | 1 | 2016 | 107 | 0.140 |
Why?
|
Patient Care Team | 3 | 2016 | 2515 | 0.130 |
Why?
|
Program Development | 2 | 2016 | 1294 | 0.130 |
Why?
|
Bone Marrow Cells | 2 | 2014 | 2410 | 0.130 |
Why?
|
Unnecessary Procedures | 1 | 2019 | 418 | 0.130 |
Why?
|
Medication Errors | 2 | 2012 | 783 | 0.120 |
Why?
|
Aged, 80 and over | 9 | 2021 | 58952 | 0.120 |
Why?
|
Biomedical Technology | 1 | 2016 | 210 | 0.110 |
Why?
|
Middle Aged | 14 | 2022 | 220853 | 0.110 |
Why?
|
Patient Satisfaction | 2 | 2016 | 3453 | 0.110 |
Why?
|
Focus Groups | 2 | 2018 | 1413 | 0.110 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1746 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3691 | 0.100 |
Why?
|
Peer Group | 1 | 2018 | 691 | 0.100 |
Why?
|
Radiation Oncology | 1 | 2018 | 563 | 0.100 |
Why?
|
Anemia, Refractory | 1 | 2011 | 17 | 0.100 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 161 | 0.100 |
Why?
|
Self Administration | 1 | 2013 | 387 | 0.100 |
Why?
|
Male | 17 | 2024 | 360693 | 0.100 |
Why?
|
Quality Indicators, Health Care | 2 | 2019 | 1789 | 0.100 |
Why?
|
Pandemics | 2 | 2022 | 8663 | 0.090 |
Why?
|
Insurance Carriers | 1 | 2013 | 155 | 0.090 |
Why?
|
Oxazolidinones | 1 | 2011 | 98 | 0.090 |
Why?
|
Education | 1 | 2014 | 536 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1427 | 0.090 |
Why?
|
Professional Practice | 1 | 2013 | 313 | 0.090 |
Why?
|
Retrospective Studies | 7 | 2023 | 80674 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3512 | 0.090 |
Why?
|
Anemia, Sideroblastic | 1 | 2011 | 109 | 0.090 |
Why?
|
Piperazines | 1 | 2021 | 2522 | 0.090 |
Why?
|
Interprofessional Relations | 1 | 2016 | 990 | 0.090 |
Why?
|
Acetamides | 1 | 2011 | 257 | 0.090 |
Why?
|
Research Report | 1 | 2012 | 367 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 8003 | 0.080 |
Why?
|
Patients | 1 | 2016 | 906 | 0.080 |
Why?
|
Aged | 12 | 2018 | 169288 | 0.080 |
Why?
|
Time Factors | 6 | 2020 | 39957 | 0.080 |
Why?
|
Hospice Care | 1 | 2016 | 678 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 3027 | 0.080 |
Why?
|
Canada | 1 | 2014 | 2125 | 0.080 |
Why?
|
Health Status | 1 | 2021 | 4077 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6486 | 0.080 |
Why?
|
Total Quality Management | 1 | 2009 | 262 | 0.080 |
Why?
|
Databases, Factual | 1 | 2023 | 7966 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2015 | 2425 | 0.070 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2014 | 801 | 0.070 |
Why?
|
Employee Performance Appraisal | 1 | 2008 | 86 | 0.070 |
Why?
|
Patient Participation | 1 | 2016 | 1445 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8519 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4246 | 0.070 |
Why?
|
Mental Health | 1 | 2021 | 3251 | 0.070 |
Why?
|
Adult | 8 | 2020 | 221119 | 0.070 |
Why?
|
Hospital Information Systems | 1 | 2009 | 394 | 0.070 |
Why?
|
Patient Readmission | 1 | 2020 | 3265 | 0.070 |
Why?
|
Teaching | 1 | 2014 | 1171 | 0.070 |
Why?
|
Prosthesis-Related Infections | 1 | 2011 | 488 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5300 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2014 | 955 | 0.070 |
Why?
|
Young Adult | 5 | 2018 | 59221 | 0.070 |
Why?
|
Risk Assessment | 2 | 2019 | 24021 | 0.060 |
Why?
|
Family | 1 | 2016 | 3192 | 0.060 |
Why?
|
Mortality | 1 | 2017 | 2896 | 0.060 |
Why?
|
Clinical Competence | 2 | 2018 | 4788 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2015 | 22174 | 0.060 |
Why?
|
Estramustine | 1 | 2005 | 35 | 0.060 |
Why?
|
Risk Factors | 4 | 2019 | 74239 | 0.060 |
Why?
|
Cognition | 1 | 2022 | 6988 | 0.060 |
Why?
|
Outpatients | 1 | 2013 | 1598 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12052 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2015 | 5250 | 0.060 |
Why?
|
Survival Analysis | 1 | 2017 | 10088 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5493 | 0.060 |
Why?
|
Odds Ratio | 1 | 2015 | 9652 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2015 | 64681 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2017 | 11119 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11733 | 0.050 |
Why?
|
Carboplatin | 1 | 2005 | 793 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6919 | 0.050 |
Why?
|
Taxoids | 1 | 2005 | 668 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6341 | 0.050 |
Why?
|
Logistic Models | 1 | 2015 | 13249 | 0.040 |
Why?
|
Inpatients | 1 | 2012 | 2545 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29687 | 0.040 |
Why?
|
Appendiceal Neoplasms | 1 | 2021 | 155 | 0.040 |
Why?
|
Registries | 1 | 2015 | 8247 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15308 | 0.040 |
Why?
|
Internship and Residency | 1 | 2018 | 5885 | 0.040 |
Why?
|
Social Support | 1 | 2008 | 2175 | 0.040 |
Why?
|
Population Surveillance | 1 | 2008 | 2598 | 0.040 |
Why?
|
Biomedical Research | 1 | 2012 | 3434 | 0.030 |
Why?
|
Mutation | 1 | 2021 | 30002 | 0.030 |
Why?
|
Health Services | 1 | 2021 | 750 | 0.030 |
Why?
|
Infusions, Parenteral | 1 | 2016 | 398 | 0.030 |
Why?
|
Venous Thromboembolism | 1 | 2009 | 1869 | 0.030 |
Why?
|
Adolescent | 2 | 2016 | 88298 | 0.030 |
Why?
|
Facility Design and Construction | 1 | 2016 | 85 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2005 | 2220 | 0.030 |
Why?
|
Cohort Studies | 3 | 2013 | 41496 | 0.030 |
Why?
|
Protein Conformation | 1 | 2021 | 3933 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7407 | 0.030 |
Why?
|
Benchmarking | 1 | 2018 | 1045 | 0.020 |
Why?
|
Health Policy | 2 | 2014 | 2679 | 0.020 |
Why?
|
Environment | 1 | 2016 | 1122 | 0.020 |
Why?
|
Pyridines | 1 | 2021 | 2872 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 15637 | 0.020 |
Why?
|
Arthroplasty | 1 | 2011 | 310 | 0.020 |
Why?
|
Polypharmacy | 1 | 2011 | 307 | 0.020 |
Why?
|
Electronic Health Records | 2 | 2018 | 4822 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2014 | 667 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1118 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9327 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2014 | 1506 | 0.020 |
Why?
|
Erythropoietin | 1 | 2011 | 719 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1807 | 0.020 |
Why?
|
Erythrocyte Transfusion | 1 | 2011 | 569 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 54435 | 0.020 |
Why?
|
Medication Adherence | 1 | 2018 | 2175 | 0.020 |
Why?
|
Reminder Systems | 1 | 2009 | 386 | 0.020 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 696 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2009 | 601 | 0.020 |
Why?
|
Ketoconazole | 1 | 2005 | 97 | 0.010 |
Why?
|
Mitoxantrone | 1 | 2005 | 148 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2317 | 0.010 |
Why?
|
Patient Compliance | 1 | 2015 | 2688 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2013 | 1662 | 0.010 |
Why?
|
Emotions | 1 | 2016 | 2742 | 0.010 |
Why?
|
Linear Models | 1 | 2013 | 5869 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2005 | 883 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2005 | 11101 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6180 | 0.010 |
Why?
|
Reoperation | 1 | 2011 | 4303 | 0.010 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2011 | 1413 | 0.010 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2011 | 1394 | 0.010 |
Why?
|
Obesity, Morbid | 1 | 2011 | 1277 | 0.010 |
Why?
|
Area Under Curve | 1 | 2005 | 1636 | 0.010 |
Why?
|
Genetic Testing | 1 | 2013 | 3537 | 0.010 |
Why?
|
Medical Records | 1 | 2005 | 1409 | 0.010 |
Why?
|
Informed Consent | 1 | 2005 | 1008 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3198 | 0.010 |
Why?
|
Internet | 1 | 2009 | 3096 | 0.010 |
Why?
|
Comorbidity | 1 | 2011 | 10516 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10218 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 12976 | 0.010 |
Why?
|
Data Collection | 1 | 2005 | 3320 | 0.010 |
Why?
|
Anticoagulants | 1 | 2009 | 4795 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10756 | 0.010 |
Why?
|
Pain | 1 | 2005 | 5072 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 12159 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39126 | 0.000 |
Why?
|